DeepMed Research

Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Clinical Trials

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Phase 1

Recruiting

Conditions: Metastatic Melanoma

Interventions: Biological: TILT-123
Biological: TIL
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: TILT Biotherapeutics Ltd.

Target Recruit Count: 9

Registration Number: NCT06961786

Locations: 🇩🇰
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University, Copenhagen, Denmark

Phase I/II Clinical Trial f CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1

Not yet recruiting

Conditions: Melanoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: TIL Product

First Posted Date: 2025-05-07

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 36

Registration Number: NCT06961357

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Drug: Busulfan
Procedure: Chest Radiography
Procedure: Computed Tomography
Procedure: Echocardiography Test
Drug: Fludarabine
Drug: Melphalan
Procedure: Multigated Acquisition Scan
Drug: Placebo Administration
Procedure: Positron Emission Tomography
Radiation: Total-Body Irradiation
Drug: Venetoclax

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 244

Registration Number: NCT06954987

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Not yet recruiting

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Biological: Ciltacabtagene Autoleucel
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Dasatinib
Drug: Fludarabine
Procedure: Positron Emission Tomography
Drug: Quercetin

First Posted Date: 2025-04-23

Last Posted Date: 2025-05-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 44

Registration Number: NCT06940297

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors

Phase 1

Not yet recruiting

Conditions: Solid Tumor

Interventions: Biological: CD73/AXL.HypoSti.CAR-T cells
Drug: Albumin-Bound Paclitaxel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 30

Registration Number: NCT06939270

Locations: 🇨🇳
Biotherapeutic Department, Chinese PLA General Hospital, Beijing, Beijing, China

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Phase 1

Not yet recruiting

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Acute Undifferentiated Leukemia
Mixed Phenotype Acute Leukemia
Recurrent Acute Undifferentiated Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Chest Radiography
Drug: Cytarabine
Procedure: Echocardiography Test
Biological: Filgrastim
Drug: Fludarabine
Procedure: Hematopoietic Cell Transplantation
Drug: Idarubicin
Procedure: Multigated Acquisition Scan
Procedure: Pheresis
Radiation: Total-Body Irradiation
Procedure: Biospecimen Collection

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 36

Registration Number: NCT06928662

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Substudy B: CLL Patients

Phase 1

Not yet recruiting

Conditions: Relapsed CLL
Refractory CLL
Refractory Lymphoma

Interventions: Drug: BAFF CAR-T
Drug: Obinutuzumab
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Paolo Caimi, MD

Target Recruit Count: 18

Registration Number: NCT06916767

Locations: 🇺🇸
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio, United States

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Phase 1

Not yet recruiting

Conditions: Malignancy, Hematologic
Neoplasms, Hematologic
Neoplasms, Hematopoietic
Blood Cancer
Hematological Neoplasms
Hematopoietic Malignancies
Dysmyelopoietic Syndromes
Hematopoetic Myelodysplasia
Myeloid Leukemia, Acute
Nonlymphoblastic Leukemia, Acute

Interventions: Drug: aldesleukin
Drug: cyclophosphamide
Drug: fludarabine phosphate
Biological: Individual Patient TCR-Transduced PBL
Device: TruSight Oncology (TSO) 500

First Posted Date: 2025-04-01

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT06904066

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Phase 1

Recruiting

Conditions: Lupus Erythematosus, Systemic

Interventions: Biological: AZD0120
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2025-03-27

Last Posted Date: 2025-05-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 150

Registration Number: NCT06897930

Locations: 🇺🇸
Research Site, Seattle, Washington, United States

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Phase 1

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Biological: IX001 TCR-T injection
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2025-03-27

Last Posted Date: 2025-04-02

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 9

Registration Number: NCT06898385

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy